Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26708155

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Feb
First author
Shaw AT

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Feb;17(2):134-135. doi: 10.1016/S1470-2045(15)00555-0.
    note
    Source null
    related pmid
    26708154
    relationship
    Comment in
  2. citation
    Transl Lung Cancer Res. 2016 Jun;5(3):343-6. doi: 10.21037/tlcr.2016.03.05.
    note
    Source null
    related pmid
    27411885
    relationship
    Comment in
  3. citation
    J Thorac Dis. 2016 Oct;8(10):E1311-E1316. doi: 10.21037/jtd.2016.10.82.
    note
    Source null
    related pmid
    27867615
    relationship
    Comment in
  4. citation
    J Thorac Dis. 2016 Nov;8(11):2997-3002. doi: 10.21037/jtd.2016.11.76.
    note
    Source null
    related pmid
    28066567
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2017 Mar;18(3):e134. doi: 10.1016/S1470-2045(17)30077-3.
    note
    Source null
    related pmid
    28271868
    relationship
    Erratum in

Authors and identifiers

  1. name
    Shaw AT
    type
    Author
  2. name
    Gandhi L
    type
    Author
  3. name
    Gadgeel S
    type
    Author
  4. name
    Riely GJ
    type
    Author
  5. name
    Cetnar J
    type
    Author
  6. name
    West H
    type
    Author
  7. name
    Camidge DR
    type
    Author
  8. name
    Socinski MA
    type
    Author
  9. name
    Chiappori A
    type
    Author
  10. name
    Mekhail T
    type
    Author
  11. name
    Chao BH
    type
    Author
  12. name
    Borghaei H
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Shaw AT
    type
    Author
  2. name
    Gandhi L
    type
    Author
  3. name
    Gadgeel S
    type
    Author
  4. name
    Riely GJ
    type
    Author
  5. name
    Cetnar J
    type
    Author
  6. name
    West H
    type
    Author
  7. name
    Camidge DR
    type
    Author
  8. name
    Socinski MA
    type
    Author
  9. name
    Chiappori A
    type
    Author
  10. name
    Mekhail T
    type
    Author
  11. name
    Chao BH
    type
    Author
  12. name
    Borghaei H
    type
    Author
bibliography ids
  1. nci-bib-5308114c610f5bba15a96a77
book metadata
content sha256
656a4d49064ebdde62c9a9f65b9f4d9e97b8ecc14d26bf0df561d3647485d10f
document type
citation
dois
  1. 10.1016/S1470-2045(15)00488-X
electronic publication date
display
2015 Dec 19
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26708155
immutable id
pubmed:26708155@656a4d49064ebdde62c9a9f65b9f4d9e97b8ecc14d26bf0df561d3647485d10f
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
234-242
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Feb;17(2):134-135. doi: 10.1016/S1470-2045(15)00555-0.
    note
    Source null
    related pmid
    26708154
    relationship
    Comment in
  2. citation
    Transl Lung Cancer Res. 2016 Jun;5(3):343-6. doi: 10.21037/tlcr.2016.03.05.
    note
    Source null
    related pmid
    27411885
    relationship
    Comment in
  3. citation
    J Thorac Dis. 2016 Oct;8(10):E1311-E1316. doi: 10.21037/jtd.2016.10.82.
    note
    Source null
    related pmid
    27867615
    relationship
    Comment in
  4. citation
    J Thorac Dis. 2016 Nov;8(11):2997-3002. doi: 10.21037/jtd.2016.11.76.
    note
    Source null
    related pmid
    28066567
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2017 Mar;18(3):e134. doi: 10.1016/S1470-2045(17)30077-3.
    note
    Source null
    related pmid
    28271868
    relationship
    Erratum in
outcomes validated
false
pmid
26708155
provenance
batch id
948d34b0dea86780a31d
provider
NCBI PubMed ESummary
record sha256
3f34f3e528b4c9612e01196a25f7197143e6db60c55d37a115776d89146b52f8
response sha256
11c34185eb9e4ea0d3c4d255d31806495349b0f097d492c4e135946541bf4bb5
retrieved at
2026-09-09T23:47:15.495091+00:00
publication date
display
2016 Feb
precision
month
year
2016
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26708155/
title
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Preserved source evidence · Not medical advice